UBT251
UBT251 Injection Phase II Study (Overweight or Obesity)
The United Bio-Technology (Hengqin) Co · Phase 2 · Completed · Enrollment 205
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| UBT251 Injection 2.0 mg | n/r | n/r | n/r | n/r | n/r |
| UBT251 Injection 4.0 mg(ID 0.5 mg) | n/r | n/r | n/r | n/r | n/r |
| UBT251 Injection 4.0 mg(ID 1.0 mg) | n/r | n/r | n/r | n/r | n/r |
| UBT251 Injection 6.0 mg | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.